Autologous HBV-TCR T Cell Therapy (LioCyx-M) for the Treatment of Hepatocellular Carcinoma

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

December 1, 2027

Study Completion Date

December 1, 2028

Conditions

Hepatocellular Carcinoma

Interventions

DRUG

LioCyx-M, HBV antigen-specific TCR-redirected T cells

Via intravenous (IV) infusion

Trial Locations (1)

RECRUITING

Gaobo Boren Hospital, Beijing

All Listed Sponsors

collaborator

Beijing GoBroad Hospital

OTHER

lead

Lion TCR Pte. Ltd.

INDUSTRY